Immunohistochemistry identified significantly reduced Ly6G+ TAN and CD163+ M2 TAM stainings on primary tumor sections from anti-CHI3L1- compared to IgG control-treated mice, and add-on reductions of both markers in chitin-treated primary tumors (Fig. 9D,E). This evidence concerns the gene CD163 and neoplasm.